We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App

Nucleic Acid Amplification Test Detects COVID-19 Without Using Instrument or Electricity

By LabMedica International staff writers
Posted on 21 Apr 2022
Print article
Image: Domus Simplex test for SARS-CoV-2 (all known variants) under development (Photo courtesy of Domus Diagnostics)
Image: Domus Simplex test for SARS-CoV-2 (all known variants) under development (Photo courtesy of Domus Diagnostics)

COVID-19 cases, hospitalizations and deaths have receded in most parts of the world, but public health officials continue to monitor for possible surges of the BA.2 variant, which is currently being seen in the US, Europe, and China. Many countries, especially those with lower incomes and fragile health systems, remain vulnerable to COVID-19 outbreaks. At-home tests offering PCR-like accuracy are oftentimes unaffordable for many low-income households when faced with having to purchase multiple test kits for use over multiple days. Researchers will soon begin clinical testing of a COVID-19 testing platform that could significantly address the global need for accessible, rapid, Nucleic Acid Amplification Tests (NAAT) that can be used by an unskilled user anywhere in the world without the need for an instrument or electricity.

Domus Diagnostics’ (Park City, UT, USA) reverse transcription loop-mediated isothermal amplification (RT-LAMP) test is intended to provide affordable, user-friendly, accurate and effective infectious disease detection to the general public. The Domus test uses a simple process in which the person collects a nasal swab specimen from each nostril, inserts a collection chamber into a card, and waits 30 minutes for the result. The Domus test, which can achieve testing accuracy on par with a PCR test, does not require instrumentation, electricity, or cold chain logistics. NAATs like Domus can detect COVID-19 earlier than widely available, at-home antigen tests, which are more effective when a person is contagious.

Domus’ goal is to produce a test that can be manufactured anywhere and sold at a price that is lower than what antigen tests. Initially, the test will be submitted for approval through the World Health Organization so that it can be provided to governments and public health organizations in developing countries at cost to address their need for accessible COVID-19 testing. Because the Domus platform can detect multiple targets from one sample, Domus will seek FDA authorization for a multiplex test for COVID-19 and seasonal flu after clinical trials have been completed.

“Domus’ vision is to provide a simple to use, highly accurate test that can be produced affordably at scale,” said Paul Chapman, president and CEO of Domus Diagnostics. “Our talented team of scientists and engineers have developed a truly innovative NAAT testing solution that can finally address those testing gaps that have existed for decades between the developing world and the West. This impact, we hope, will extend far beyond the current crisis and will enable better global preparedness for future pandemics.”

Related Links:
Domus Diagnostics 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Rapid Test
AQ+ COVID-19 Ag Rapid Test

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more


view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.